MetrioPharm is a clinical-stage company that develops safe and effective treatments based on first-in-class self-regulating immunomodulators for inflammatory and infectious diseases. The company's lead candidate MP1032 is an oral small molecule immune modulator targeting dysregulated mitochondrial metabolism in immune cells, aimed at reducing the side effects of corticosteroid therapy. MetrioPharm focuses on rare diseases and plans to expand indications for MP1032.

MetrioPharm AG

Affimed is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies using its ROCK® (Redirected Optimized Cell Killing) platform.

Affimed

A pharmaceutical company that is now part of Johnson & Johnson Innovative Medicine, focused on developing and delivering medicines for a range of health conditions.

Janssen

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Metric
Company Name	MetrioPharm AG	Affimed	Janssen	Novartis AG
Symbol				NOVN
MSH ID	COM:METRIOPHARM	COM:AFFIMED	COM:JANSSEN	COM:NOVARTIS
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Biotechnology	Pharmaceuticals
Country	DE	DE		CH
Stage
Employee Count		105		101.70K
Website	metriopharm.com	affimed.com	janssen.com	novartis.com
LinkedIn		affimed-ag		novartis
Founders

Metric
Market Cap				220.95B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue				46.66B
Revenue (LTM)
Revenue (NTM)
Gross Profit				34.19B
EBITDA				18.47B
Operating Income				9.77B
Net Income				14.85B
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.75
Operating Profit Margin				0.25
EBITDA Margin				0.40
Net Profit Margin				0.33
Return on Equity				0.39
Return on Assets				0.17
Return on Capital Employed				0.17

COM:METRIOPHARM

MetrioPharm AG

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				14.33
P/B Ratio				4.56
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				4.83
EV Multiple				11.29

Metric
Days Sales Outstanding				67.09
Days Payables Outstanding				124.77
Days Inventory Outstanding				169.11
Operating Cycle				232.40
Cash Conversion Cycle				110.44
Asset Turnover				0.53

Metric
Operating Cash Flow				14.46B
Free Cash Flow				11.71B
Cash Flow to Debt				0.55
Operating Cash Flow/Sales				0.31
Free Cash Flow Yield				0.05

Metric
Cash & Equivalents				13.39B
Accounts Receivable				-1.50B
Inventory				5.91B
Goodwill				23.34B
Debt to Capitalization				0.41
Debt to Assets				0.26
Current Ratio				1.16
Quick Ratio				0.88

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.02
R&D to Revenue				0.23
SG&A to Revenue